Letters to the Editor

Vyse TJ Späth PJ Davies KA . Hereditary complement factor I deficiency. Q J Med. 1994;87(7):385–401.

Philippe P Jakob S Späth P . Deficit congenital du facteur I du complement (FI) et infections septiques recidivants. Helv Paed Acta. 1987;42(1):74.

Affentranger P Morell A Späth P Seger R . Registry of primary immunodeficiencies in Switzerland. Immunodeficiency. 1993;4(1–4):193–195.

Späth PJ . Inflammation-attenuating effects of intravenous immunoglobulin. In: Faist E Baue AE Schildberg FW , eds. The Immune Consequences of Trauma, Shock and Sepsis – Mechanisms and Therapeutic Approaches – Immunomodulation and the Inflammatory Response. Lengerich, Germany: Pabst Scientific Publishers; 1996:985–998.

Basta M Kirshbom P Frank MM Fries LF . Mechanism of therapeutic effect of high-dose intravenous immunoglobulin: Attenuation of acute, complement-dependent immune damage in a guinea pig model. J Clin Invest. 1989;84(6):1974–1981.

Basta M Dalakas MC . High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J Clin Invest. 1994;94(5):1729–1735.

Lutz HU Stammler P Jelezarova E Nater M Späth PJ . High doses of immunoglobulin G attenuate immune aggregate-mediated complement activation by enhancing physiologic cleavage of C3b in C3bn-IgG complexes. Blood. 1996;88(1):184–193.

Lutz HU Stammler P Bianchi V . Intravenously applied IgG stimulates complement attenuation in a complement-dependent autoimmune disease at the amplifying C3 convertase level. Blood. 2004;103(2):465–472.

Ito S Aihara Y Yokota S . Intravenous gamma globulin for atypical hemolytic uremic syndrome. Pediatr Nephrol. 2007;22(6):909.

Meglic A Grosek S Benedik-Dolnicar M Avcin T . Atypical haemolytic uremic syndrome complicated by microangiopathic antiphospholipid-associated syndrome. Lupus. 2008;17(9):842–845.

Watt T Warshaw B Katzenstein HM . Atypical hemolytic uremic syndrome responsive to steroids and intravenous immune globulin. Pediatr Blood Cancer. 2009;53(1):90–91.

Hofer J Riedl M Rosales A . Remission and recurrence free 3 years follow up in a patient with factor H antibody associated atypical HUS after induction therapy with plasma exchange and maintenance therapy with IVIG and MMF. Pediatr Nephrol. 2013;28(8):1567–1568.